ResMed, Inc. Hits New 52-Week Low at USD 210.67

ResMed, Inc., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 210.67 as of April 30, 2026. This significant price point reflects a notable shift in the stock's performance, especially when compared to its 52-week high of USD 293.81. Over the past year, ResMed's stock has shown a modest performance increase of 1.02%, which stands in stark contrast to the S&P 500's impressive gain of 29.45%. The company's market capitalization is currently valued at approximately USD 43,243 million, indicating its substantial presence in the market. Financial metrics reveal a price-to-earnings (P/E) ratio of 29.00, alongside a dividend yield of 3.17%. ResMed also boasts a return on equity of 23.77%, showcasing its efficiency in generating profits from shareholders' equity. The company's debt-to-equity ratio stands at -0.12, indicating a strong balance sheet. As the stock navigates this new low, it remains a focal point for those observing trends within the Pharmaceuticals & Biotechnology industry.